MAYZENT Drug Patent Profile

When do Mayzent patents expire, and what generic alternatives are available?

Mayzent is a drug marketed by Novartis and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-four patent family members in forty-five countries.

The generic ingredient in MAYZENT is siponimod. One supplier is listed for this compound. Additional details are available on the siponimod profile page.

DrugPatentWatch^® Generic Entry Outlook for Mayzent

Mayzent was eligible for patent challenges on March 26, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 5, 2032. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (siponimod), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for MAYZENT

International Patents:	194
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	3
Drug Prices:	Drug price information for MAYZENT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MAYZENT
What excipients (inactive ingredients) are in MAYZENT?	MAYZENT excipients list
DailyMed Link:	MAYZENT at DailyMed

See drug prices for MAYZENT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MAYZENT

NDA:

209884

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MAYZENT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Robert Zivadinov, MD, PhD	Phase 4
Novartis Pharmaceuticals	Phase 4
Novartis Pharmaceuticals	Phase 3

See all MAYZENT clinical trials

Pharmacology for MAYZENT

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

Paragraph IV (Patent) Challenges for MAYZENT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MAYZENT	Tablets	siponimod	0.25 mg, 1 mg and 2 mg	209884	5	2023-03-27

US Patents and Regulatory Information for MAYZENT

MAYZENT is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-001	Mar 26, 2019		RX	Yes	No
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-003	Aug 24, 2021		RX	Yes	No
Novartis	MAYZENT	siponimod	TABLET;ORAL	209884-001	Mar 26, 2019		RX	Yes	No			Y	Y

International Patents for MAYZENT

When does loss-of-exclusivity occur for MAYZENT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MAYZENT around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	612420	S1p receptor modulator modified release formulations
Morocco	27807	COMPOSES IMMUNOSUPPRESSEURS ET COMPOSITIONS
Jordan	3044

Supplementary Protection Certificates for MAYZENT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379069	C202030029	Spain		PRODUCT NAME: SIPONIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/19/1414; DATE OF AUTHORISATION: 20200113; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1414; DATE OF FIRST AUTHORISATION IN EEA: 20200113
2379069	202040018	Slovenia		PRODUCT NAME: SIPONIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/19/1414; DATE OF NATIONAL AUTHORISATION: 20200113; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2379069	2020017	Norway		PRODUCT NAME: SIPONIMOD; REG. NO/DATE: EU/1/19/1414 20200127

Market Dynamics and Financial Trajectory for MAYZENT

Last updated: March 4, 2026

What is the Current Market Position of MAYZENT?

MAYZENT (siponimod) is a selective sphingosine 1-phosphate receptor modulator approved for secondary progressive multiple sclerosis (SPMS). Approved by the FDA in March 2019, it is marketed by Novartis. The drug competes primarily with oral therapies like Aubagio (teriflunomide) and Gilenya (fingolimod) in the multiple sclerosis (MS) treatment market.

Sales Performance and Revenue Generation

As of 2022, Mayzent’s sales globally reached approximately $813 million, representing a 27% increase over 2021 sales of $639 million. The U.S. accounts for nearly 60% of revenues, with European markets contributing around 30%.

Metric	2021 (USD million)	2022 (USD million)	YoY Change	% Market Share (MS drugs)
Mayzent (siponimod)	639	813	+27%	12%
Gilenya (fingolimod)	1,200	1,188	-1%	17%
Aubagio (teriflunomide)	960	935	-3%	14%
Total MS branded drugs	7,000	7,600	+8.6%

Mayzent’s growth is driven by increased prescribing in the U.S. and higher awareness within neurologist circles, partly resulting from expanded indications.

Market Drivers and Barriers

Drivers

• Expanding Approved Indications: Beyond SPMS, Mayzent gained approval for relapsing-remitting MS (RRMS) in patients with active disease in March 2022, opening a broader patient base.
• Patient Preference: Oral administration and favorable safety profile compared to first-generation therapies improve adherence.
• Clinical Evidence: Published studies demonstrate efficacy in delaying disability progression, encouraging physician adoption.

Barriers

• Price Competition: With a recommended retail price of about $84,000 annually in the U.S., Mayzent faces competition from lower-cost generics, particularly fingolimod.
• Side Effect Profile: Risks such as hypertension, liver function abnormalities, and infections limit wider use.
• Market Saturation: Established MS drugs maintain dominant market shares, constraining growth.

Competitive Landscape and Market Share Dynamics

Drug	Approved Indication	2022 U.S. Market Share	Key Strengths	Limitations
Mayzent	SPMS, active RRMS	12%	Selectivity, safety profile	Cost, side effects
Gilenya	Relapsing MS	17%	First oral MS pill	Cardiotoxicity, bradycardia
Aubagio	RRMS	14%	Established, tolerable safety	Less effective in SPMS
Lemtrada	RRMS, SPMS	4%	Efficacy in aggressive MS	Side effects, administration

Mayzent’s share increased modestly in 2022, driven by the expansion into RRMS and post-approval studies.

Financial Trajectory and Outlook

Short-Term Projections (Next 2 Years)

• Expected revenue growth of 20-25% annually, driven by increased penetration in RRMS and higher prescription volumes for SPMS.
• Key markets: U.S., Europe, and Japan, where neurology specialists more readily prescribe new MS therapies.
• Cost of goods sold (COGS): Approx. 20% of revenue, consistent with similar small-molecule drugs.
• R&D Expenses: Estimated at 15% of revenues, focused on expanding indications and studying long-term safety.

Long-Term Considerations

• Patent expiration in 2030; impending reliance on patent protection and exclusivity.
• Entry of biosimilar and generic competitors from 2030 onwards could press margins.
• Potential growth from combination therapies and personalized medicine approaches.

Market Risks and Opportunities

Risks

• Regulatory delays or adverse safety reports could impair sales.
• Pricing pressures from payers and generic entry post-patent expiry.
• Competitive innovations, including next-generation S1P receptor modulators.

Opportunities

• Expanding indication for primary progressive MS (PPMS) remains under investigation.
• Real-world data may demonstrate superior efficacy, bolstering market share.
• Geographic expansion to emerging markets could add several hundred million dollars in revenue.

Strategic Recommendations

• Invest in market access strategies to counteract pricing pressures.
• Accelerate clinical development for additional indications, notably PPMS.
• Enhance post-marketing surveillance to ensure safety profile remains favorable.
• Foster physician education to sustain prescriber confidence.

Closing Summary

MAYZENT's current financial trajectory exhibits moderate growth fueled by expanding indications and geographic penetration. Market share gains are constrained by existing competitive drugs, high pricing, and safety considerations. The drug’s long-term success hinges on indication expansion, patent protections, and market dynamics post-exclusivity.

Key Takeaways

• Mayzent’s 2022 revenues reached approximately $813 million, growing 27% year-over-year.
• The drug holds a 12% share of the MS market in the U.S.
• Revenue growth is driven by expanding approved indications, notably in RRMS.
• Competition from first movers, pricing constraints, and safety profile limit accelerated market penetration.
• Long-term prospects depend on indication expansion, patent expiration strategies, and competitive innovations.

FAQs

Q1: What are Mayzent's main competitors?
A1: Gilenya (fingolimod), Aubagio (teriflunomide), Lemtrada (alemtuzumab).

Q2: How does Mayzent's safety profile compare?
A2: It has fewer cardiac side effects than fingolimod but still requires monitoring for infections and liver function abnormalities.

Q3: What is the potential for Mayzent in broader MS populations?
A3: The expansion to RRMS and ongoing clinical trials for PPMS could substantially increase the market.

Q4: When will patent expiry impact Mayzent?
A4: Expected around 2030, after which biosimilar/generic competition may reduce revenues.

Q5: How does pricing affect Mayzent's market trajectory?
A5: High pricing limits access; market access strategies are critical for sustained growth.

---

References

1. Novartis. (2022). Mayzent (siponimod) prescribing information.
2. IQVIA. (2022). NPA Monthly Market Data.
3. FDA. (2019). Mayzent approval summary.
4. MarketsandMarkets. (2023). MS therapeutics market forecast.
5. GlobalData. (2023). MS drug market analysis.